Boehringer-Ingelheim, Roche Drug Recalls Point to Manufacturing Problems; B-I Recall Reflects “Original” Marketing Tactic

The Financial Times reported yesterday that Boehringer-Ingelheim and Roche have both had to recall drugs in the U.S. and Europe within the past few weeks due to manufacturing quality issues.  Roche recalled its HIV treatment, Viracept, in Europe and some developing nations a few weeks ago because the drug contained chemical impurities, and higher than normal levels of methane sulfonic acid ethylester. B-I's recall  of its pet arthritis drug, Synoquin, is particularly interesting, since it was reportedly motivated by a competitor, the Nutraceuticals supplier Vet Plus.  Vet Plus ran lab tests on the B-I product which found that it contained less than the required amount of active ingredient. ...More arguments for use of process analytical technologies during manufacturing. But, as competition in the industry intensifies,  could more companies adapt Vet Plus' "guerilla" pharma marketing strategy? Analyze the competitor's product,  then publicize any quality problems discovered... cGMPs as marketing tool...
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


  • <p>It is great to have the opportunity to read a good quality article with useful information on topics that plenty are interested on.I concur with your conclusions and will eagerly look forward to your future updates <a href="">puzzle games</a> <a href="">adventure games</a> <a href="">Action games</a> <a href="">Strategy games</a> </p>


RSS feed for comments on this page | RSS feed for all comments